Evidence map›Paper›PMID 36072966›Full record

ArticleJournal of oncology2022

Downregulation of S100A9 Reverses Cisplatin-Resistance and Inhibits Proliferation and Migration in Hypopharyngeal Carcinoma.

Shiyu Zeng, Guolin Tan, Tiansheng Wang, Xianyao Wang, Zheng Zhou, Jian Xiao, Tieqi Li, Gehou Zhang, Wei Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shiyu ZengDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Guolin TanDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Tiansheng WangDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Xianyao WangDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Zheng ZhouDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Jian XiaoDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Tieqi LiDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Gehou ZhangDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.
Wei LiDepartment of Otolaryngology-Head Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province 410013, China.ORCID https://orcid.org/0000-0001-9911-2384
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Patients with hypopharyngeal carcinoma (HPC) often progress to an advanced clinical stage at diagnosis. Cisplatin has been widely used in first-line chemotherapy for advanced HPC. However, acquired chemotherapeutic resistance leads to recurrence, metastasis, and a poor survival rate. Therefore, identifying new drug targets to improve treatment effects is still in need. Methods: To screen the differential expression genes (DEGs) and proteins (DEPs), we conducted transcriptomic and proteomic analysis on cisplatin-sensitive cell lines (FaDu) and cisplatin-resistant cell lines (FaDu/DDP) of hypopharyngeal carcinoma. DEGs and DEPs, possibly the most associated with cisplatin-resistance, were verified by real-time polymerase chain reaction (RT-PCR) and western blot (WB), respectively, and the biological function of the screened S100A9 was further tested by CCK8, wound healing, and transwell assays. Results: We identified S100A9 as a target for resensitizing the response to cisplatin in an acquired resistance model. S100A9 overexpression was significantly related to cisplatin resistance. Functional studies in vitro models demonstrated that downregulation of S100A9 overcame cisplatin-resistance and inhibited proliferation and migration. Later, we verified that downregulation of S100A9 suppressed the interleukin-6 (IL6) expression and epithelial-mesenchymal transition (EMT) pathway. Conclusion: In all, S100A9 plays a crucial role in cisplatin-resistance, proliferation, and migration of HPC. Targeting S100A9 may become a novel strategy for the treatment of HPC.

Identifiers

PMID36072966
PMCPMC9444389
OpenAlexW4293724495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.